Denise Treue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Denise Treue has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Denkert
Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, Germany
27 shared publications - Andreas Schneeweiss
National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
26 shared publications - Frederik Marmé
Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
26 shared publications - Hans-Peter Sinn
Sektion Gynäkopathologie, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Germany
26 shared publications - Peter Andreas Fasching
Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
26 shared publications - Sibylle Loibl
German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany
26 shared publications
Latest Publications
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Distribution of PIK3CA mutations status on any, exon and hotspot level in the trial cohort (A) according to molecular subtype as well as (B) in the HER2pos cohort, stratified by HR status.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Distribution of PIK3CA mutations status on any, exon and hotspot level in the trial cohort (A) according to molecular subtype as well as (B) in the HER2pos cohort, stratified by HR status.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Survival analysis (DFS and OS) in the full cohort using Kaplan-Meier plots with log rank tests for statistical evaluation stratified by PIKC mutations status.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Survival analysis (DFS and OS) in the full cohort using Kaplan-Meier plots with log rank tests for statistical evaluation stratified by PIKC mutations status.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
PCR rates of HER2pos subgroup stratified by anti-HER2 treatment regimes
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
PCR rates of HER2pos subgroup stratified by anti-HER2 treatment regimes
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
PCR rates of HER2pos subgroup stratified by anti-HER2 treatment regimes
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
PCR rates of HER2pos subgroup stratified by anti-HER2 treatment regimes
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
PCR rates in molecular subgroups
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
PCR rates in molecular subgroups
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
PCR rates in molecular subgroups
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
PCR rates in molecular subgroups
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Logistic regression model using PIK3CA mutation level status predicting pCR as binary endpoint in molecular subtypes and in HER2pos cohort stratified by HR status.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Logistic regression model using PIK3CA mutation level status predicting pCR as binary endpoint in molecular subtypes and in HER2pos cohort stratified by HR status.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Distribution of PIK3CA mutations status on any, exon and hotspot level in the trial cohort (A) according to molecular subtype as well as (B) in the HER2pos cohort, stratified by HR status.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Distribution of PIK3CA mutations status on any, exon and hotspot level in the trial cohort (A) according to molecular subtype as well as (B) in the HER2pos cohort, stratified by HR status.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Survival analysis (DFS and OS) in the full cohort using Kaplan-Meier plots with log rank tests for statistical evaluation stratified by PIKC mutations status.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Survival analysis (DFS and OS) in the full cohort using Kaplan-Meier plots with log rank tests for statistical evaluation stratified by PIKC mutations status.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Logistic regression model using PIK3CA mutation level status predicting pCR as binary endpoint in molecular subtypes and in HER2pos cohort stratified by HR status.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Logistic regression model using PIK3CA mutation level status predicting pCR as binary endpoint in molecular subtypes and in HER2pos cohort stratified by HR status.